Skip to content
Home/Companies/Biotech/PsiOxus Therapeutics

PsiOxus Therapeutics

Biotech·UK·Active·5yr hold
Entry
2021
Hold
5yr
Status
Active

Who owns PsiOxus Therapeutics?

PsiOxus Therapeutics is a British Biotech company, currently owned by Rosetta Capital since 2021.

Hand-verified · updated 2026-06-30

Open JSON · CC-BY
Rosetta Capital
Investor
Rosetta Capital
Rosetta Capital V · 2021 · Secondaries

Key facts

HQUK
SectorBiotech
StatusActive

More from Rosetta Capital V

Other portfolio companies in the same fund.

Carrick Therapeutics
Carrick Therapeutics
Active
BiotechIreland· 2021
Immunocore
Immunocore
Active
BiotechUK· 2021
Inivata
Inivata
Exited 2021
HealthTechUK· 2021
to NeoGenomics
Mereo BioPharma
Mereo BioPharma
Active
BiotechUK· 2021
Mission Therapeutics
Mission Therapeutics
Active
BiotechUK· 2021
ReNeuron
ReNeuron
Active
BiotechUK· 2021

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns PsiOxus Therapeutics?

PsiOxus Therapeutics is currently owned by Rosetta Capital, through Rosetta Capital V, since 2021.

When did Rosetta Capital acquire PsiOxus Therapeutics?

Rosetta Capital acquired PsiOxus Therapeutics in 2021.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue